HOME >> BIOLOGY >> NEWS
Early HIV treatment fails to restore memory T cells

Most of the bodys memory T cells vanish within weeks after a person is infected with the HIV virus. In a study from the Aaron Diamond AIDS Research Center and the Bernard-Nocht Institute appearing in the international open-access journal PLoS Medicine, researchers report that these memory T cells, mostly found in the digestive tract, tend not to return to normal even after years of treatment for HIV.

In recent years, HIV infection has been shown to deplete the bodys memory T cells quite rapidly. In particular, the memory cells in the intestinal lining are decimated within days, while the T cells usually measured in the blood fall much more gradually, typically over several years. Although T cells in the blood can return and remain at normal levels when HIV infection is treated with antiviral drugs, it has been unclear whether the intestinal mucosal memory cells return as well. By performing intestinal biopsies on volunteers who started HIV treatment shortly after infection, the researchers found that, unlike in blood, intestinal T cells remained low even after several years of HIV treatment in 70% of volunteers, even though only a tiny fraction of these cells were found to be expressing HIV. Furthermore, they found that the level of immune activation in the gastrointestinal tract remained elevated despite treatment.

The finding that intestinal immune cells do not return to normal in most people with HIV despite years of treatment raises the concern that clinical problems will result over time. Fortunately, this does not appear to be the case in most people currently being treated for HIV, some for as long as 10 years, but the results of this study suggest that vigilance is warranted for infections or other gastrointestinal problems resulting from prolonged impairment of immunity.

These results also suggest that treatments to preserve immune function early after infection should be studied, and in particular that an HIV vaccine may need to s
'"/>

Contact: Andrew Hyde
press@plos.org
44-122-346-3330
Public Library of Science
4-Dec-2006


Page: 1 2

Related biology news :

1. Early fire risk for mountains near Los Angeles
2. Early environmental exposure may accelerate age-related neurodegeneration
3. Early exposure to indoor fungus molecules may protect infants against future allergies
4. Early-stage sperm cells created from human bone marrow
5. Early Europeans unable to stomach milk
6. Early Earth haze may have spurred life, says University of Colorado study
7. Early detection
8. Early family experience can reverse the effects of genes, UCLA psychologists report
9. Early to bed, early to rise
10. Early exposure to synthetic estrogen puts DES Daughters at higher risk for breast cancer
11. Top researcher-educators receive Presidential Early Career Award for Scientists and Engineers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com , ... biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European Hematology ... Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase 1 ...
(Date:7/1/2020)... ... July 01, 2020 , ... Cure Glioblastoma, ... glioblastoma—the most common and aggressive adult brain cancer—announced today the appointments of its ... are charged with supporting the organization’s initiatives and overall vision. , "Senior Fellows ...
(Date:6/25/2020)... ... 24, 2020 , ... eClinical Solutions LLC , a ... accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ) on ... severe COVID-19. This is the first study of an XPO1 inhibitor in patients ...
Breaking Biology News(10 mins):
(Date:6/28/2020)... ... June 25, 2020 , ... Lumeda Inc. (“Lumeda”), ... announced the company has entered a license agreement with Roswell Park Comprehensive Cancer ... exclusive rights to Roswell Park intellectual property surrounding a novel medical device and ...
(Date:6/23/2020)... ... 23, 2020 , ... DeCurtis Corporation, the premier provider of ... Fournier has been appointed CEO and President. Founder and former CEO, David DeCurtis, ... “DeCurtis Corporation has been on an incredible journey for the last twenty years, ...
(Date:6/23/2020)... ... 23, 2020 , ... Nobilis Therapeutics, a biopharmaceutical company focused ... an Investigational New Drug application (IND) with the U.S. Food & Drug Administration ... NBTX-001 in patients with panic disorder (PD). , "Adding a PD trial to ...
(Date:6/11/2020)... ... June 09, 2020 , ... ... of a Small Business Innovation Research (SBIR) program funded by the National Institute ... Toxin Detection in the Field”. The project’s goal was to engineer and develop ...
Breaking Biology Technology:
Cached News: